Good reception for Receptos U-T San Diego Moussatos says Receptos is likely to be an even bigger success for MS than daclizumab, sold as by Roche as Zenapax. An estimated 400,000 people in the United States and 2.5 million people worldwide have multiple sclerosis. The disease damages the ... |
